Novartis AG (NYSE:NVS)

74.22
Delayed Data
As of 3:58pm ET
 +0.65 / +0.88%
Today’s Change
73.21
Today|||52-Week Range
94.19
-11.61%
Year-to-Date
Teva to Discontinue a Fremanezumab Study on Cluster Headache
Jun 18 / Zacks.com - Paid Partner Content
Galmed (GLMD) Soars on Positive NASH Data on Aramchol
Jun 13 / Zacks.com - Paid Partner Content
Novartis Announces Positive Data on CAR-T Therapy, Kymriah
Jun 18 / Zacks.com - Paid Partner Content
Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study
Jun 12 / Zacks.com - Paid Partner Content
Large Cap Pharma Stock Outlook: Short-Term Struggle Likely
Jun 18 / Zacks.com - Paid Partner Content
Alzheimer's Research Stumbles Again: What's the Road Ahead?
Jun 12 / Zacks.com - Paid Partner Content
Roche Announces Positive Data on Gazyva and MS Drug Ocrevus
Jun 15 / Zacks.com - Paid Partner Content
Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris
Jun 08 / Zacks.com - Paid Partner Content
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
Jun 14 / Zacks.com - Paid Partner Content
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
Jun 07 / Zacks.com - Paid Partner Content
Allergan (AGN) Presents Positive Data on Glaucoma Candidate
Jun 14 / Zacks.com - Paid Partner Content